e-ISSN: 2717-7157
  • Home
  • Aims and Scope
  • Editorial Board
  • Instructions for Authors
  • Table of Contents
  • Contact
  • Türkçe
Current Issue
Archive
Search
Online Subscription Login
Subscription Form
Most Popular
Download Articles Read Articles
Automated Perimetry
Carbonic Anhydrase Inhibitors
Intra Ocular Lens Power Calculation and Optic Biometry...
Visual Field Defects in Glaucoma
Visual Field Defect and Retinal Nerve Fiber Layer Defect in a Case of Optic Nerve Head Drusen...
Current Minimal Invasive Angle Procedures Without Implants for the Treatment of Glaucoma...
Intra Ocular Lens Power Calculation and Optic Biometry...
Automated Perimetry
Carbonic Anhydrase Inhibitors
Visual Field Defect and Retinal Nerve Fiber Layer Defect in a Case of Optic Nerve Head Drusen...
Glokom-Katarakt 2007 , Vol 2 , Num 3
Turkish Abstract Abstract PDF Similar Articles Mail to Author
Carbonic Anhydrase Inhibitors
Selim DOĞANAY1, Penpe Gül FIRAT2
1İnönü Üniversitesi Tıp Fakültesi Göz Hastalıkları A.D., Doç. Dr.
2İnönü Üniversitesi Tıp Fakültesi Göz Hastalıkları A.D., Asist. Dr.
Carbonic anhydrase inhibitors (CAI) are among the most powerful intraocular pressure lowering agents used in ophthalmology. There are two form of CAI. Systemic form of CAI’s, acetozolamide, have been using since 1954. Introduction of dorzolamide, the first topical CAI, marks an important development in glaucoma theraphy. Brinzolamide, second topical CAI, have been using in ophthalmolgy since 1998. The main advantage of the topical CAIs, dorzolamid and brinzolamide, is the marked reduction in the systemic side effects associated with the oral agents. However, serious systemic side effects may be ocur in some patients.
In our study, we aim to review general pharmocologic properties, both glaucoma and other usage field in ophthalmolgy of the systemic CAI and topicals CAIs.
Keywords : Carbonic anhydrase inhibitors, glaucoma
Home
Aims and Scope
Editorial Board
Instructions for Authors
Table of Contents
Contact